Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Achieve Life Sciences, Inc. (ACHV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.97-0.13 (-1.83%)
At close: 04:00PM EST
Advertisement
Sign in to post a message.
  • d
    dave
    Chart is ready to blast ..... primary results of orca 2 are knew now 12 weeks after 06/30 . pfizer at the corner for the buy out ........hope so !!! chiantix is dead go ahead with cytisinicline
    Bullish
  • C
    Carlos Molina
    At its new high forever
  • M
    Mike
    Look at the float amount.

    We’ll be printing with news.
  • a
    alan
    Volume way up last three months gaining interest. Stage 2 trials paper work final approval Jan 12. Stage 3 will start then. I don’t know why it can not be fast tracked with all the results from Europe and Asia. Price target $13. Will be a great 2020 for ACHV.
  • B
    Brian
    This is a no brainer strong buy. Low float. Sound management. Stock is trading at CASH VALUE. $28M market cap. $27M in cash. No debt. Has enough cash to do BOTH Phase III studies alone if they so choose. But you know someone wants a piece of this pie...so expect a buyout or collaborative partnership to be announced in the future. BUY AND HOLD people. This will rocket up soon. And if the results presented end of this week are positive, see you north of $10 in a blink.
  • J
    John
    Attended the investor day event today. Very well done. The panel of experts made a compelling case that Cyt efficacy is at least as good as Chantix and the side effect and AE profile is much better (lower rates of vivid dreams and nausea). Docs want there to be a new drug to try too as Chantix has a stigma and many patients don’t want it. I have done my own consultations with independent experts on smoking cessation and there is no doubt that Cyt will pass its trials and get to market. So it’s a question of market opportunity... Chantix goes generic in 2020, and Pfizer will probably look to partner with ACHV to extend the franchise. Cyt can do $500m+ per year in US in hands of Pfizer. Maybe even $1B+. I see a deal where PFE covers the development costs and provides ACHV with 15% royalty. I think we could wake up one day with a deal where ACHV pops up to $10, $15, or maybe even higher. I wouldn’t be surprised if this happens in the next 3 months.
  • M
    Momo Finder
    ACHV announced that an abstract featuring data from the Phase 2b ORCA-1 trial has been accepted for oral presentation at the SRNT-E Annual Conference, to be held in Oslo , September 12-14, 2019 . Gapping up premarket watching for this to hold and push higher, good luck healthcare on watch today https://stock-watch.market/biotech
    If you’ve ever invested in the stock market or traded a single share, chances are you’ve familiarized yourself with the “hot markets”. These are the ones that consistently see enormous volatility and gains that most only dream of. More times than not
    If you’ve ever invested in the stock market or traded a single share, chances are you’ve familiarized yourself with the “hot markets”. These are the ones that consistently see enormous volatility and gains that most only dream of. More times than not
    stock-watch.market
  • T
    Thomas
    Equities research analysts at HC Wainwright assumed coverage on shares of Achieve Life Sciences (NASDAQ:ACHV) in a report released on Tuesday, The Fly reports. The firm set a “buy” rating and a $2.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 301.61% from the company’s current price.
  • A
    Amanda
    WHY ACHV PRICE WILL CONTINUE TO SOAR...HERE ARE THE FACTS:

    ACHV just completed a public offering with no warrants on July 1, 2020. There will not be another offering any time soon. Earnings and corporate up date on Thursday, August 6, 2020. Analysts rank "BUY" with a median price target of $6 and a high of $10. Phase 3 clinical results of new drug for quiting smoking coming out at September conference. This drug is far superior to any other drug on the market because of none of the side effects of other drugs. Huge earning potential for ACHV in a $1 billion market. This company is a solid investment opportunity!
    Bullish
  • J
    Jeff
    This should bounce nicely in AH today and tomorrow. This selloff is way overdone, from $1.40 today to .49 with an offering. Everyone knew they needed to conduct an offering to fund the next phase trial so it isn't a surprise. Yes .60 cents was a little lower than I would have liked to see it priced at but they now have the cash necessary to conduct Phase 3 with potential NDA around the corner or mid to late 2020. This has great potential and even with the new shares of 9.5 million and existing share count of 8.35 million (Total 18 million) this should rise to a market cap of about 50 million which would be $2.80 per share or so fair value right now. Load up for a nice run from here, the reward ratio will serve you well. With new shares added the current market cap is 8.8 million which is a joke... Cheers!
  • s
    steve
    The problem is that they will need a large capital raise either dilution or a high interest rate loan. Seen this game before...
  • A
    Amanda
    So glad I did not sell today. Instead, I bought an extra 10,000 shares during the dip into the 0.60s. I am going to hold at least through the earnings report and corporate update on Thursday, August 6 which will send the stock price even higher. More good news on phase 3 clinical results coming out in September so I may hold through then. Reading all the facts with several analysts giving a price target as high as $10 within this year, the best strategy would be to accumulate as many shares as possible and just hold for the BIG pay off $$$!!
  • f
    frank
    we will see 6.55 tomorrow
  • B
    Brian
    READ THIS: "Achieve has a license and supply agreement with partner Sopharma to provide support on development and manufacturing as well as an exclusive supply of cytisinicline. While cytisinicline is considered a natural product and cannot be patented, a successful approval from the FDA will provide FIVE YEARS of exclusivity for the product in the US and TEN YEARS in EU countries. Additionally, a novel salt-form of cytisinicline has been patented which could provide future protections for the product beyond the regulatory exclusivity periods. An improved product offered to a large global population that is trying to quit provides an attractive market for Achieve Life Sciences, especially given there have been no new smoking cessation treatments in over a decade. With over half of the population of smokers trying to quit, we estimate there will be about 25 million Americans and several hundred million individuals globally in the addressable market when cytisinicline is approved.

    Key reasons to own ACHV shares:

    ‣ Proven asset with use in over 20 million smokers
    ‣ Preliminary data shows improved efficacy and favorable side effect profile vs. current products
    ‣ Shorter therapy duration vs. other NRT or Chantix
    ‣ Dual acting MoA reduces cravings, withdrawal symptoms & prevents rush from smoking
    ‣ Previous Phase III studies completed in over 2,000 subjects demonstrate safety and efficiacy
    ‣ Pursuing smoking population of ~40 million in US and over one billion worldwide
    ‣ Smoking cessation medication market value of $4.6 billion
    ‣ Company maintains sufficient cash to complete currently active trials
  • N
    Nozzleman
    10/2 big conference presentation---looking for some key data
  • a
    allen
    Thanks jumped in.
  • a
    alan
    All they did was get patent approved. Still need stage 3 trial started need approval from FDA to distribute. The reverse split allows them to sell more shares they have no choice.. To complete stage 3 trials costs millions of dollars.
  • E
    ERIC
    Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Achieve Life Sciences (ACHV) today and set a price target of $10.00. The
    Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Achieve Life Sciences (ACHV) today and set a price target of $10.00. The
    www.smarteranalyst.com
  • S
    Smallcap Lover
    The global healthcare industry is predicted to grow at a rate of 5.4% between 2017-2022, according to a report by Deloitte, reaching $10.059 trillion-dollars. The rise of personalized medicine, inc…
    The global healthcare industry is predicted to grow at a rate of 5.4% between 2017-2022, according to a report by Deloitte, reaching $10.059 trillion-dollars. The rise of personalized medicine, inc…
    smallcapreporter.wordpress.com
  • G
    Guerilla Trades
    buy and hold. So easy money the next days.
Advertisement
Advertisement